Spyre Therapeutics, Inc. (SYRE) Income Statement

The absence of revenue in nine of ten quarters means the income statement reflects a pre-commercial clinical-stage profile rather than a scalable operating business. The lone 2025Q4 revenue figure does not establish a repeatable trend and should be treated cautiously until its nature, such as a licensing or collaboration payment, is clarified in filings. Investors should monitor whether future periods show recurring revenue or whether the business continues to rely on episodic receipts.

Because gross profit is zero or unavailable in most periods, operating leverage cannot be assessed in the conventional sense, and the loss trajectory is driven almost entirely by R&D intensity. SG&A remained comparatively stable between roughly $11M and $17M, indicating that overhead is not the primary source of expansion. The pattern suggests a deliberate clinical investment cycle, though the reported figures alone do not confirm the strategic rationale or the timing of eventual returns.

R&D consistently represents the largest expense line, and its growth from $32.6M in 2024Q2 to $89.2M in 2026Q3 is the principal driver of losses. SG&A has remained relatively contained, suggesting disciplined overhead relative to program spend. The cost mix implies that the value of the enterprise is tied to pipeline outcomes, which the income statement alone cannot evaluate.